ATTENTION: The software behind KU ScholarWorks is being upgraded to a new version. Starting July 15th, users will not be able to log in to the system, add items, nor make any changes until the new version is in place at the end of July. Searching for articles and opening files will continue to work while the system is being updated.
If you have any questions, please contact Marianne Reed at mreed@ku.edu .
Molecular engineering improves antigen quality and enables integrated manufacturing of a trivalent subunit vaccine candidate for rotavirus
dc.contributor.author | Dalvie, Neil C. | |
dc.contributor.author | Brady, Joseph R. | |
dc.contributor.author | Crowell, Laura E. | |
dc.contributor.author | Tracey, Mary Kate | |
dc.contributor.author | Biedermann, Andrew M. | |
dc.contributor.author | Kaur, Kawaljit | |
dc.contributor.author | Hickey, John M. | |
dc.contributor.author | Kristensen, D. Lee, II | |
dc.contributor.author | Bonnyman, Alexandra D. | |
dc.contributor.author | Rodriguez-Aponte, Sergio A. | |
dc.contributor.author | Whittaker, Charles A. | |
dc.contributor.author | Bok, Marina | |
dc.contributor.author | Vega, Celina | |
dc.contributor.author | Mukhopadhyay, Tarit K. | |
dc.contributor.author | Joshi, Sangeeta B. | |
dc.contributor.author | Volkin, David B. | |
dc.contributor.author | Parreño, Viviana | |
dc.contributor.author | Love, Kerry R. | |
dc.contributor.author | Love, J. Christopher | |
dc.date.accessioned | 2022-01-05T22:01:11Z | |
dc.date.available | 2022-01-05T22:01:11Z | |
dc.date.issued | 2021-05-01 | |
dc.identifier.citation | Dalvie, N.C., Brady, J.R., Crowell, L.E. et al. Molecular engineering improves antigen quality and enables integrated manufacturing of a trivalent subunit vaccine candidate for rotavirus. Microb Cell Fact 20, 94 (2021). https://doi.org/10.1186/s12934-021-01583-6 | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/32347 | |
dc.description.abstract | Background Vaccines comprising recombinant subunit proteins are well-suited to low-cost and high-volume production for global use. The design of manufacturing processes to produce subunit vaccines depends, however, on the inherent biophysical traits presented by an individual antigen of interest. New candidate antigens typically require developing custom processes for each one and may require unique steps to ensure sufficient yields without product-related variants.Results We describe a holistic approach for the molecular design of recombinant protein antigens—considering both their manufacturability and antigenicity—informed by bioinformatic analyses such as RNA-seq, ribosome profiling, and sequence-based prediction tools. We demonstrate this approach by engineering the product sequences of a trivalent non-replicating rotavirus vaccine (NRRV) candidate to improve titers and mitigate product variants caused by N-terminal truncation, hypermannosylation, and aggregation. The three engineered NRRV antigens retained their original antigenicity and immunogenicity, while their improved manufacturability enabled concomitant production and purification of all three serotypes in a single, end-to-end perfusion-based process using the biotechnical yeast Komagataella phaffii.Conclusions This study demonstrates that molecular engineering of subunit antigens using advanced genomic methods can facilitate their manufacturing in continuous production. Such capabilities have potential to lower the cost and volumetric requirements in manufacturing vaccines based on recombinant protein subunits. | en_US |
dc.publisher | BMC | en_US |
dc.rights | © The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License. | en_US |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | Pichia pastoris | en_US |
dc.subject | Subunit vaccine | en_US |
dc.subject | Quality by design | en_US |
dc.subject | Biomanufacturing | en_US |
dc.title | Molecular engineering improves antigen quality and enables integrated manufacturing of a trivalent subunit vaccine candidate for rotavirus | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Kaur, Kawaljit | |
kusw.kuauthor | Hickey, John M. | |
kusw.kuauthor | Joshi, Sangeeta B. | |
kusw.kuauthor | Volkin, David B. | |
kusw.kudepartment | Pharmaceutical Chemistry | en_US |
kusw.kudepartment | Vaccine Analytics and Formulation Center | en_US |
dc.identifier.doi | 10.1186/s12934-021-01583-6 | en_US |
dc.identifier.orcid | https://orcid.org/ 0000-0003-0921-3144 | en_US |
kusw.oaversion | Scholarly/refereed, publisher version | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.identifier.pmid | PMC8088319 | en_US |
dc.rights.accessrights | openAccess | en_US |